Cost-Per-Responder Analysis of Bimekizumab (IL-17A/F inhibitor) against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, based on Matching-Adjusted Indirect Comparisons (MAIC)

Congress: ISPOR Europe 2024

Objective:

Bimekizumab is an IgG1 monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, recently approved for the treatment of patients with active psoriatic arthritis (PsA) in the European Union. This study compares the cost per responder (CPR) of bimekizumab with therapies targeting IL-17A and IL-12/23 (secukinumab and ustekinumab) for the treatment of patients with PsA in Spain. Based on the response rates (MDA, ACR50 and ACR70) published in MAIC at week 52, the CPR analyses showed, in most cases, it was more efficient to treat patients with PsA in Spain with bimekizumab than with secukinumab or ustekinumab.